Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.57), $0.04 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $9.5 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.